

Special Issue

Molecular Pathways in Metastasis of Lung Cancer

Message from the Guest Editor

Lung cancer is the leading cause of cancer related death worldwide. In addition to the histological classification into mainly non-small cell adenocarcinomas and squamous cell carcinomas and small cell lung carcinomas, the growing understanding of oncogenic molecular pathways has led to a pronounced diversification of therapeutic options and thus to a significant improvement in the prognosis of patients. In particular, however, the pronounced tendency to develop distant metastases, especially in the brain, liver, bones and adrenal gland, severely limits the long-term prognosis of affected patients. In this special issue, the molecular oncogenic pathways in lung cancer metastases will be highlighted from the perspective of basic, translational and clinical research with the overall goal of improving the use of existing therapeutics and identifying new potential drug targets.

Guest Editor

Dr. Hanibal Bohnenberger

Institute of Pathology, University Medical Center Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany

Deadline for manuscript submissions

closed (31 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164935

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)